What is SNY's current stock price?

As of now, SNY is trading at $48.32, with a daily change of +0.60%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

SNY Stock Analysis & IQ Rating | Sanofi

SNY SNY Badge

Sanofi

$48.32

+$0.29 | +0.60%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

alert Latest Updates

Night.Owl Yesterday at 09:08

Trinity Biotech stole the late-session spotlight after announcing agreements to strengthen its capital structure alongside a major order for nine million TrinScreen HIV tests, signaling renewed demand in global testing m...

BQ Stock IQ

Login to see Sanofi (SNY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

SNY Target Price

Login to display

Strengths

SNY Rewards

Trading below its fair value

SNY Rewards

Upgraded on attractively valued

SNY Price Performance

$49.15 (-1.69%)

$45.54 (+6.10%)

$45.66 (+5.83%)

$49.19 (-1.77%)

1year

6month

3month

1month

SNY Risk Level

SNY has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

SNY Analysts Opinion

SNY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

SNY Analysts Opinion

SNY Analysts opinion is positive and it remained unchanged from the past 3 months

SNY Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

84%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

75%

0%

75%

SNY Street Sentiment

SNY Street Sentiment is extremely bullish and have positive views on the near-term outlook

SNY Performance Sentiment

Sentiments overview associated with SNY events and the stock performance.

84%

13%

Positive

Negative

51 out of 61
events present

8 out of 61
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$48.18

Resistance
Price

$47.44

Current Price Range

$50.62

Show methods +

Linked to SNY

IQ

Close Price

Change

PFE

3.74

24.88

-1.31%

REGN

4.19

785.17

+0.75%

MRK

4.24

105.12

+0.40%

ABBV

4.21

228.80

+0.39%

AZN

4.27

92.10

+0.64%

SNY Latest Analysis +

Press Release: Sanofis Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia. Sanofi'.s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopeniaParis December 23 2025 – The European Commission has approved Wayrilz (rilzabrutinib) a novel oral reversible Bruton'.s tyrosine kinase (BTK) inhibitor as a new treatment for immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments. This follows the by th

Today

$48.32 | +0.60%

Activity

Potential

Press Release: Sanofis Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia. Sanofis Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia

Today

$48.32 | +0.60%

Activity

Press Release: Sanofi and Regenerons Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma. Sanofi and Regeneron'.s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaParis and Tarrytown NY December 23 2025. The Ministry of Health Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of bronchial asthma in children aged 6 to 11 years with severe or refractory disease

Today

$48.32 | +0.60%

Activity

Sanofi: Dupixent Now Approved In Japan For Children Aged 6 To 11 Years . (RTTNews) - Sanofi (SNY SAN.PA) said The Ministry of Health Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent or dupilumab for the treatment of bronchial asthma in children aged 6 to 11 years with severe or refractory disease whose s

Today

$48.32 | +0.60%

Activity

Sanofi a Top Ranked SAFE Dividend Stock With 4.6% Yield (SNY). Sanofi (Symbol: SNY) has been named to the Dividend Channel International S.A.F.E. 10 list signifying an international stock with above-average DividendRank statistics including a strong 4.6% yield as well as a superb track record of at least five years of dividend gr

Mon Dec 22, 2025

$48.03 | -0.25%

Potential

Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation. Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation

Fri Dec 19, 2025

$48.18 | +0.40%

Activity

Sanofi (SNY) Shares Under Pressure After JPMorgan and Guggenheim Downgrades. We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Sanofi is among the most undervalued stocks. Between December 8 and December 10 2025 SNY faced a series of analyst rating adjustments that tempered investor sentiment. The Fly reported on Monday December 8 2025 that J.P. Morgan downgraded SNY from [….]

Wed Dec 17, 2025

$48.14 | +1.48%

Potential

Sanofi Receives EMA Orphan Designation For Efdoralprin Alfa . (RTTNews) - Sanofi (SNY SNYNF SAN.PA) announced that the European Medicines Agency (EMA) has granted orphan designation to efdoralprin alfa (SAR447537) formerly known as INBRX-101.

Wed Dec 17, 2025

$48.14 | +1.48%

Activity

Sanofis efdoralprin alfa receives EU orphan designation for rare lung disease.

Wed Dec 17, 2025

$48.14 | +1.48%

Activity

SNY Stock Down on Double Trouble With Multiple Sclerosis Drug. Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib and a phase III study fails to hit its primary endpoint.

Tue Dec 16, 2025

$47.44 | -0.79%

Momentum

FAQ About SNY Stock Insights

What is SNY current stock price?

What are SNY stock strengths?

What is SNY Risk Level?

What is SNY market cap and volume?

What is SNY current Stock IQ?

Should I buy SNY stock right now?

Is SNY a Strong Buy right now?

What does a 'Strong Buy' rating mean for SNY?

What does a 'Strong Sell' rating mean for SNY?

What factors influence SNY's Stock IQ?

Explore our SNY Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored SNY Stock Strategies
Effective Risk Management

FIND US ON

Receive our SNY Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

SNY SNY Badge

Sanofi

Current Price

$48.32

+$0.29 | +0.60%

52W High

$60.12

MKT CAP

$117.23B

52W Low

$44.62

VOL

$1.47M

P/E Ratio

11.11

AVG VOL

$2.57M

RSI

46.81

TREND

Downtrend

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

SNY Rewards

Trading below its fair value

SNY Rewards

Upgraded on attractively valued

Linked to SNY

Symbol

IQ

Close

Change

PFE

3.74

24.88

-1.31%

REGN

4.19

785.17

+0.75%

MRK

4.24

105.12

+0.40%

ABBV

4.21

228.80

+0.39%

AZN

4.27

92.10

+0.64%

SNY Price Performance

$49.15 (-1.69%)

$45.54 (+6.10%)

$45.66 (+5.83%)

$49.19 (-1.77%)

1year

6month

3month

1month

SNY Analysts Opinion

SNY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

SNY Analysts Opinion

SNY Analysts opinion is positive and it remained unchanged from the past 3 months

SNY Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

84%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

75%

0%

75%

SNY Street Sentiment

SNY Street Sentiment is extremely bullish and have positive views on the near-term outlook

SNY Risk Level

SNY has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

SNY Performance Sentiment

Sentiments overview associated with SNY events and the stock performance.

84%

13%

Positive

Negative

51 out of 61
events present

8 out of 61
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$48.18

Resistance
Price

$47.44

Current Price Range

$50.62

Show methods +

SNY Stock IQ

Login to unlock Sanofi (SNY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

SNY Latest Analysis

Night.Owl Yesterday at 09:08

Trinity Biotech stole the late-session spotlight after announcing agreements to strengthen its capital structure alongside a major order for nine million TrinScreen HIV tests, signaling renewed demand in global testing m...

Press Release: Sanofis Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia. Sanofi'.s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopeniaParis December 23 2025 – The European Commission has approved Wayrilz (rilzabrutinib) a novel oral reversible Bruton'.s tyrosine kinase (BTK) inhibitor as a new treatment for immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments. This follows the by th

Today

$48.32 | +0.60%

Activity

Potential

Press Release: Sanofis Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia. Sanofis Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia

Today

$48.32 | +0.60%

Activity

Press Release: Sanofi and Regenerons Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma. Sanofi and Regeneron'.s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaParis and Tarrytown NY December 23 2025. The Ministry of Health Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of bronchial asthma in children aged 6 to 11 years with severe or refractory disease

Today

$48.32 | +0.60%

Activity

Sanofi: Dupixent Now Approved In Japan For Children Aged 6 To 11 Years . (RTTNews) - Sanofi (SNY SAN.PA) said The Ministry of Health Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent or dupilumab for the treatment of bronchial asthma in children aged 6 to 11 years with severe or refractory disease whose s

Today

$48.32 | +0.60%

Activity

Sanofi a Top Ranked SAFE Dividend Stock With 4.6% Yield (SNY). Sanofi (Symbol: SNY) has been named to the Dividend Channel International S.A.F.E. 10 list signifying an international stock with above-average DividendRank statistics including a strong 4.6% yield as well as a superb track record of at least five years of dividend gr

Mon Dec 22, 2025

$48.03 | -0.25%

Potential

Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation. Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation

Fri Dec 19, 2025

$48.18 | +0.40%

Activity

Sanofi (SNY) Shares Under Pressure After JPMorgan and Guggenheim Downgrades. We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Sanofi is among the most undervalued stocks. Between December 8 and December 10 2025 SNY faced a series of analyst rating adjustments that tempered investor sentiment. The Fly reported on Monday December 8 2025 that J.P. Morgan downgraded SNY from [….]

Wed Dec 17, 2025

$48.14 | +1.48%

Potential

Sanofi Receives EMA Orphan Designation For Efdoralprin Alfa . (RTTNews) - Sanofi (SNY SNYNF SAN.PA) announced that the European Medicines Agency (EMA) has granted orphan designation to efdoralprin alfa (SAR447537) formerly known as INBRX-101.

Wed Dec 17, 2025

$48.14 | +1.48%

Activity

Sanofis efdoralprin alfa receives EU orphan designation for rare lung disease.

Wed Dec 17, 2025

$48.14 | +1.48%

Activity

SNY Stock Down on Double Trouble With Multiple Sclerosis Drug. Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib and a phase III study fails to hit its primary endpoint.

Tue Dec 16, 2025

$47.44 | -0.79%

Momentum

Discover SNY Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of SNY. We're here to help you make informed investment decisions today.

FIND US ON

Receive our SNY Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

SNY Stock trends

SNY Stock performance

SNY Stock analysis

SNY investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing SNY

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing SNY

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

SNY Stock Analysis & IQ Rating | Sanofi

BQ Stock IQ

SNY Target Price

SNY Risk Level

SNY Analysts Opinion

SNY Street Sentiment

SNY Performance Sentiment

Technical Price Levels

Explore our SNY Stock insights

Receive our SNY Daily Alerts

SNY Street Sentiment

SNY Risk Level

Technical Price Levels

Discover SNY Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of SNY. We're here to help you make informed investment decisions today.

Receive our SNY Daily Alerts

SNY Alerts